Lyra Therapeutics Files 8-K
Ticker: LYRA · Form: 8-K · Filed: Sep 4, 2025 · CIK: 1327273
| Field | Detail |
|---|---|
| Company | Lyra Therapeutics, INC. (LYRA) |
| Form Type | 8-K |
| Filed Date | Sep 4, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, corporate-update
TL;DR
Lyra Therapeutics filed an 8-K on Sept 4, 2025. Standard update.
AI Summary
Lyra Therapeutics, Inc. filed an 8-K on September 4, 2025, reporting other events and financial statements. The company, formerly known as Arsenal Medical, Inc., is incorporated in Delaware and headquartered in Watertown, Massachusetts.
Why It Matters
This filing indicates Lyra Therapeutics is providing updates to the SEC, which could include significant operational or financial developments.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically reports on significant events but doesn't inherently carry immediate risk on its own.
Key Numbers
- 001-39273 — Commission File Number (SEC identifier for Lyra Therapeutics)
- 84-1700838 — IRS Employer Identification No. (Tax identification for Lyra Therapeutics)
Key Players & Entities
- Lyra Therapeutics, Inc. (company) — Registrant
- September 4, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Watertown, Massachusetts (location) — Principal Executive Offices
- Arsenal Medical, Inc. (company) — Former Company Name
FAQ
What specific 'Other Events' are being reported by Lyra Therapeutics in this 8-K filing?
The filing indicates 'Other Events' as an item information, but the specific details of these events are not provided in the excerpt.
What is the significance of the 'Financial Statements and Exhibits' being filed?
This suggests that Lyra Therapeutics is providing updated financial information or related documentation to the SEC as required.
When was Lyra Therapeutics incorporated, and where are its principal executive offices located?
Lyra Therapeutics, Inc. was incorporated in Delaware and its principal executive offices are located at 480 Arsenal Way, Watertown, Massachusetts.
What were Lyra Therapeutics' former company names?
Lyra Therapeutics, Inc. was formerly known as Arsenal Medical, Inc., Arsenal Vascular, Inc., and 480 Biomedical, Inc.
What is the SIC code for Lyra Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Lyra Therapeutics, Inc. is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Filing Stats: 430 words · 2 min read · ~1 pages · Grade level 11.6 · Accepted 2025-09-04 08:01:28
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share LYRA The Nasdaq
Filing Documents
- d71675d8k.htm (8-K) — 25KB
- d71675dex991.htm (EX-99.1) — 30KB
- g71675ex99_1s10g1.jpg (GRAPHIC) — 122KB
- g71675ex99_1s11g1.jpg (GRAPHIC) — 102KB
- g71675ex99_1s12g1.jpg (GRAPHIC) — 76KB
- g71675ex99_1s13g1.jpg (GRAPHIC) — 67KB
- g71675ex99_1s14g1.jpg (GRAPHIC) — 47KB
- g71675ex99_1s15g1.jpg (GRAPHIC) — 54KB
- g71675ex99_1s16g1.jpg (GRAPHIC) — 90KB
- g71675ex99_1s17g1.jpg (GRAPHIC) — 67KB
- g71675ex99_1s18g1.jpg (GRAPHIC) — 93KB
- g71675ex99_1s19g1.jpg (GRAPHIC) — 68KB
- g71675ex99_1s1g1.jpg (GRAPHIC) — 56KB
- g71675ex99_1s20g1.jpg (GRAPHIC) — 50KB
- g71675ex99_1s2g1.jpg (GRAPHIC) — 223KB
- g71675ex99_1s3g1.jpg (GRAPHIC) — 128KB
- g71675ex99_1s4g1.jpg (GRAPHIC) — 93KB
- g71675ex99_1s5g1.jpg (GRAPHIC) — 86KB
- g71675ex99_1s6g1.jpg (GRAPHIC) — 131KB
- g71675ex99_1s7g1.jpg (GRAPHIC) — 108KB
- g71675ex99_1s8g1.jpg (GRAPHIC) — 81KB
- g71675ex99_1s9g1.jpg (GRAPHIC) — 124KB
- 0001193125-25-195384.txt ( ) — 2753KB
- lyra-20250904.xsd (EX-101.SCH) — 3KB
- lyra-20250904_lab.xml (EX-101.LAB) — 18KB
- lyra-20250904_pre.xml (EX-101.PRE) — 11KB
- d71675d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation by Lyra Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lyra Therapeutics, Inc. Date: September 4, 2025 By: /s/ Jason Cavalier Jason Cavalier Chief Financial Officer